Saturday, September 5, 2026

Is North Korea’s Latest Missile Test a Direct Challenge to U.S.-South Korea-Japan Alliance?

North Korea launched two ballistic missiles on...

North Korea’s Kim Yo-jong Calls for Measures Against Drone Incursions: What’s Next?

Kim Yo-jong commended South Korea's regret over a drone incident but stressed the need for concrete measures to prevent future violations.

9·19 Military Agreement Revival: Can South Korea Lead Amid North’s Hostility?

The Lee administration aims to restore the September 19 inter-Korean military agreement to prevent clashes and build trust amid rising tensions.

Tag: ADC

North KoreaKoreaKimMilitaryAISouth Koreamarketrelationsdevelopment

CS5001 Breakthrough: 100% Complete Remission in DLBCL Trials – What This Means for Cancer Treatment

ABL Bio's ADC candidate shows complete response in all patients in early trials for first-line treatment of DLBCL.

Samsung Bioepis, Built on Biosimilars, Expands Growth Strategy Into Novel Drugs

Samsung Bioepis is pursuing a two-track growth strategy that combines global biosimilar expansion with next-generation novel drug development, including ADC therapies.

HyDIFFUZE™: The Game-Changer in Subcutaneous ADC Delivery for Cancer Treatment

Huons Lab patents a platform technology for ADC subcutaneous injections, enhancing stability and drug delivery efficiency in biopharmaceuticals.

LegoChem expands options beyond early ADC licensing into late-stage clinical development

LegoChem Biosciences secures funding to advance ADC therapies into late-stage trials, enhancing strategic flexibility in biotech.

ABL Bio to Showcase Dual-Target ADC Candidate ABL209 at World ADC Korea 2026

ABL Bio will showcase its dual-target ADC candidate ABL209 at the World ADC Korea 2026, focusing on enhanced cancer treatment.

How Dong-A ST’s SC5024 and ADC Innovations Could Change the Game Cancer Pipeline

Dong-A ST showcased its innovative cancer pipeline at AACR 2026, featuring promising preclinical findings and advanced therapeutic strategies.

Unlocking Cancer Treatment: Celltrion’s 4 Promising ADC Drugs Enter Patient Trials in 2026

Celltrion's ADC cancer drug candidates CT-P70, CT-P71, and CT-P73 enter patient dosing, targeting various cancers with Fast Track Designation.

CT-P71: The New ADC Cancer Drug Fast-Tracked by FDA for Urothelial Carcinoma

Celltrion's CT-P71 receives FDA Fast Track designation for urothelial carcinoma, enhancing its ADC pipeline and global drug development efforts.

ABL Bio to Invest Additional $25 Million in Neok Bio to Accelerate ADC Clinical Trials

ABL Bio invests $25M in Neok Bio for bispecific antibody-drug conjugate trials, aiming for FDA-approved treatments by 2027.

ABL209 Receives FDA Approval: What This Dual Antibody ADC Means for Cancer Treatment

ABL Bio receives FDA approval for ABL209, a bispecific antibody-drug conjugate, advancing ADC development for solid tumors.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.